AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog

By
A A A

The FDA has granted priority review status to AbbVie's ( ABBV ) experimental all-oral, interferon-free therapy for the treatment of adults with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

With the new drug application (NDA) being submitted on Apr 21, AbbVie should receive a response from the FDA early in the fourth quarter.

The experimental HCV regimen has Breakthrough Therapy status which was granted by the FDA in May 2013. Breakthrough Therapy status, a new designation that became effective after Jul 9, 2012, is designed to cut short the development time of promising new treatments.

The HCV regimen has also been submitted for review in the EU where the marketing application was filed in May.

AbbVie's HCV regimen comprises ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavarin. AbbVie has presented impressive data on the experimental regimen and the NDA includes data from six phase III studies. First-round approval could very well result in this new treatment hitting the market by year end.

The HCV market is attracting a lot of interest - Gilead's ( GILD ) Sovaldi has been bringing in billions of dollars within a few months of its approval despite concerns regarding its high price. Plus there is space in the market for additional treatments. Interest in the HCV market increased further with pharma giant Merck ( MRK ) recently announcing its intention to acquire HCV focused Idenix Pharmaceuticals, Inc. ( IDIX ) for about $3.85 billion.

Several companies are looking to bring the next generation of HCV treatments to market. Gilead itself is looking to get its once-daily fixed-dose HCV cocktail treatment -- ledipasvir (NS5A inhibitor) plus Sovaldi (nucleotide analog polymerase inhibitor) -- approved in the U.S.

AbbVie is a Zacks Rank #3 (Hold) stock. Gilead, which carries a Zacks Rank #1 (Strong Buy), is a better-ranked stock.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

IDENIX PHARMA (IDIX): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: GILD , MRK , IDIX , ABBV

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com